Virulence of Group A Streptococci Is Enhanced by Human Complement Inhibitors

PLoS Pathogens

Volumn 11, Issue 7, 2015, Pages

  Ermert, David ^a,b   Shaughnessy, Jutamas ^b   Joeris, Thorsten ^c,d   Kaplan, Jakub ^a   Pang, Catherine J ^b   Kurt Jones, Evelyn A ^b   Rice, Peter A ^b   Ram, Sanjay ^b   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT INHIBITOR; VIRULENCE FACTOR; BACTERIAL ANTIGEN; OUTER MEMBRANE PROTEIN;

ARTICLE; BACTERIAL VIRULENCE; CELL PHAGOCYTOSIS; COLONY FORMING UNIT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; OPSONIZATION; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOGENICITY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; VIRULENCE;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS; MUS MUSCULUS; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; HUMANS; MICE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; VIRULENCE;

EID: 84938785113     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005043     Document Type: Article

References (59)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M, The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685–94. Epub 2005/10/29. 16253886
2. Bisno AL, Stevens DL, Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334(4):240–5. Epub 1996/01/25. 8532002
3. Nowak R, Flesh-eating bacteria: not new, but still worrisome. Science. 1994;264(5166):1665. Epub 1994/06/17. 8209244
4. Henningham A, Gillen CM, Walker MJ, Group a streptococcal vaccine candidates: potential for the development of a human vaccine. Current topics in microbiology and immunology. 2013;368:207–42. doi: 10.1007/82_2012_284 23250780
5. Ricklin D, Hajishengallis G, Yang K, Lambris JD, Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–97. Epub 2010/08/20. doi: 10.1038/ni.1923 20720586
6. Cole JN, Barnett TC, Nizet V, Walker MJ, Molecular insight into invasive group A streptococcal disease. Nature reviews Microbiology. 2011;9(10):724–36. doi: 10.1038/nrmicro2648 21921933
7. Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A, et al. Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev. 2014;27(2):264–301. Epub 2014/04/04. doi: 10.1128/CMR.00101-13 24696436
8. Frick IM, Akesson P, Cooney J, Sjobring U, Schmidt KH, Gomi H, et al. Protein H—a surface protein of Streptococcus pyogenes with separate binding sites for IgG and albumin. Mol Microbiol. 1994;12(1):143–51. Epub 1994/04/01. 8057834
9. Carlsson F, Sandin C, Lindahl G, Human fibrinogen bound to Streptococcus pyogenes M protein inhibits complement deposition via the classical pathway. Mol Microbiol. 2005;56(1):28–39. 15773976
10. Bisno AL, Brito MO, Collins CM, Molecular basis of group A streptococcal virulence. Lancet Infect Dis. 2003;3(4):191–200. Epub 2003/04/08. 12679262
11. Cunningham MW, Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470–511. Epub 2000/07/25. 10885988
12. Thern A, Stenberg L, Dahlback B, Lindahl G, Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J Immunol. 1995;154(1):375–86. Epub 1995/01/01. 7995956
13. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA, Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A. 1988;85(5):1657–61. Epub 1988/03/01. 2964038
14. Johnsson E, Thern A, Dahlback B, Heden LO, Wikstrom M, Lindahl G, A highly variable region in members of the streptococcal M protein family binds the human complement regulator C4BP. J Immunol. 1996;157(7):3021–9. Epub 1996/10/01. 8816411
15. Kihlberg BM, Collin M, Olsen A, Bjorck L, Protein H, an antiphagocytic surface protein in Streptococcus pyogenes. Infect Immun. 1999;67(4):1708–14. 10085008
16. Gomi H, Hozumi T, Hattori S, Tagawa C, Kishimoto F, Bjorck L, The gene sequence and some properties of protein H. A novel IgG-binding protein. J Immunol. 1990;144(10):4046–52. Epub 1990/05/15. 2332638
17. Carlsson F, Berggard K, Stalhammar-Carlemalm M, Lindahl G, Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein. J Exp Med. 2003;198(7):1057–68. Epub 2003/10/01. 14517274
18. Accardo P, Sanchez-Corral P, Criado O, Garcia E, Rodriguez de Cordoba S, Binding of human complement component C4b-binding protein (C4BP) to Streptococcus pyogenes involves the C4b-binding site. J Immunol. 1996;157(11):4935–9. 8943398
19. McArthur JD, Walker MJ, Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development. Mol Microbiol. 2006;59(1):1–4. 16359313
20. van Lookeren Campagne M, Wiesmann C, Brown EJ, Macrophage complement receptors and pathogen clearance. Cellular microbiology. 2007;9(9):2095–102. 17590164
21. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol. 2011;186(6):3606–14. doi: 10.4049/jimmunol.1003470 21325619
22. Blom AM, Nandakumar KS, Holmdahl R, C4b-binding protein (C4BP) inhibits development of experimental arthritis in mice. Ann Rheum Dis. 2009;68(1):136–42. Epub 2008/02/16. doi: 10.1136/ard.2007.085753 18276745
23. Czop JK, Austen KF, Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor. J Immunol. 1985;135(5):3388–93. 4045195
24. Medina E, Goldmann O, Rohde M, Lengeling A, Chhatwal GS, Genetic control of susceptibility to group A streptococcal infection in mice. J Infect Dis. 2001;184(7):846–52. 11550125
25. Suvilehto J, Jarva H, Seppanen M, Siljander T, Vuopio-Varkila J, Meri S, Binding of complement regulators factor H and C4b binding protein to group A streptococcal strains isolated from tonsillar tissue and blood. Microbes and infection / Institut Pasteur. 2008;10(7):757–63. doi: 10.1016/j.micinf.2008.04.004 18538613
26. Ermert D, Weckel A, Agarwal V, Frick IM, Bjorck L, Blom AM, Binding of complement inhibitor C4b-binding protein to a highly virulent Streptococcus pyogenes M1 strain is mediated by protein H and enhances adhesion to and invasion of endothelial cells. J Biol Chem. 2013;288(45):32172–83. Epub 2013/09/26. doi: 10.1074/jbc.M113.502955 24064215
27. Persson J, Beall B, Linse S, Lindahl G, Extreme sequence divergence but conserved ligand-binding specificity in Streptococcus pyogenes M protein. PLoS Pathog. 2006;2(5):e47. Epub 2006/05/31. 16733543
28. Gustafsson MC, Lannergard J, Nilsson OR, Kristensen BM, Olsen JE, Harris CL, et al. Factor H binds to the hypervariable region of many Streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence. PLoS Pathog. 2013;9(4):e1003323. doi: 10.1371/journal.ppat.1003323 23637608
29. Perez-Caballero D, Garcia-Laorden I, Cortes G, Wessels MR, de Cordoba SR, Alberti S, Interaction between complement regulators and Streptococcus pyogenes: binding of C4b-binding protein and factor H/factor H-like protein 1 to M18 strains involves two different cell surface molecules. J Immunol. 2004;173(11):6899–904. 15557185
30. Rittirsch D, Flierl MA, Ward PA, Harmful molecular mechanisms in sepsis. Nature reviews Immunology. 2008;8(10):776–87. doi: 10.1038/nri2402 18802444
31. Ram S, McQuillen DP, Gulati S, Elkins C, Pangburn MK, Rice PA, Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med. 1998;188(4):671–80. 9705949
32. Ram S, Cullinane M, Blom AM, Gulati S, McQuillen DP, Monks BG, et al. Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med. 2001;193(3):281–95. Epub 2001/02/07. 11157049
33. Berggard K, Lindahl G, Dahlback B, Blom AM, Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b. Eur J Immunol. 2001;31(9):2771–80. Epub 2001/09/06. 11536176
34. Meri T, Blom AM, Hartmann A, Lenk D, Meri S, Zipfel PF, The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun. 2004;72(11):6633–41. Epub 2004/10/27. 15501796
35. Hallstrom T, Jarva H, Riesbeck K, Blom AM, Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J Immunol. 2007;178(10):6359–66. Epub 2007/05/04. 17475865
36. Hallstrom T, Zipfel PF, Blom AM, Lauer N, Forsgren A, Riesbeck K, Haemophilus influenzae interacts with the human complement inhibitor factor H. J Immunol. 2008;181(1):537–45. 18566420
37. Johnsson E, Berggard K, Kotarsky H, Hellwage J, Zipfel PF, Sjobring U, et al. Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor. J Immunol. 1998;161(9):4894–901. 9794423
38. Jacks-Weis J, Kim Y, Cleary PP, Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis. J Immunol. 1982;128(4):1897–902. 7037956
39. Medina E, Lengeling A, Genetic regulation of host responses to group A streptococcus in mice. Briefings in functional genomics & proteomics. 2005;4(3):248–57.
40. Blom AM, Kask L, Dahlback B, Structural requirements for the complement regulatory activities of C4BP. J Biol Chem. 2001;276(29):27136–44. Epub 2001/05/23. 11369776
41. Fakhouri F, de Jorge EG, Brune F, Azam P, Cook HT, Pickering MC, Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int. 2010;78(3):279–86. doi: 10.1038/ki.2010.132 20445496
42. Granoff DM, Welsch JA, Ram S, Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun. 2009;77(2):764–9. doi: 10.1128/IAI.01191-08 19047406
43. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, et al. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol. 2008;180(5):3426–35. 18292569
44. Walport MJ, Complement. First of two parts. N Engl J Med. 2001;344(14):1058–66. Epub 2001/04/05. 11287977
45. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J, The role of the anaphylatoxins in health and disease. Mol Immunol. 2009;46(14):2753–66. doi: 10.1016/j.molimm.2009.04.027 19477527
46. McHugh KJ, Mandalapu S, Kolls JK, Ross TM, Alcorn JF, A novel outbred mouse model of 2009 pandemic influenza and bacterial co-infection severity. PLoS One. 2013;8(12):e82865. doi: 10.1371/journal.pone.0082865 24324838
47. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ, Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends in immunology. 2003;24(5):254–8. 12738419
48. Noursadeghi M, Bickerstaff MC, Herbert J, Moyes D, Cohen J, Pepys MB, Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection. J Immunol. 2002;169(2):913–9. 12097396.
49. Wang SM, Lu IH, Lin YL, Lin YS, Wu JJ, Chuang WJ, et al. The severity of Streptococcus pyogenes infections in children is significantly associated with plasma levels of inflammatory cytokines. Diagnostic microbiology and infectious disease. 2008;61(2):165–9. doi: 10.1016/j.diagmicrobio.2008.01.008 18296003
50. Bryant AE, Biology and pathogenesis of thrombosis and procoagulant activity in invasive infections caused by group A streptococci and Clostridium perfringens. Clin Microbiol Rev. 2003;16(3):451–62. 12857777
51. Bryant AE, Bayer CR, Chen RY, Guth PH, Wallace RJ, Stevens DL, Vascular dysfunction and ischemic destruction of tissue in Streptococcus pyogenes infection: the role of streptolysin O-induced platelet/neutrophil complexes. J Infect Dis. 2005;192(6):1014–22. 16107954
52. Ufret-Vincenty RL, Aredo B, Liu X, McMahon A, Chen PW, Sun H, et al. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. Investigative ophthalmology & visual science. 2010;51(11):5878–87.
53. Esparza-Gordillo J, Soria JM, Buil A, Almasy L, Blangero J, Fontcuberta J, et al. Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics. 2004;56(2):77–82. 15118848
54. Makou E, Herbert AP, Barlow PN, Functional anatomy of complement factor H. Biochemistry. 2013;52(23):3949–62. doi: 10.1021/bi4003452 23701234
55. Sim E, Palmer MS, Puklavec M, Sim RB, Monoclonal antibodies against the complement control protein factor H (beta 1 H). Biosci Rep. 1983;3(12):1119–31. Epub 1983/12/01. 6199050
56. Berge A, Kihlberg BM, Sjoholm AG, Bjorck L, Streptococcal protein H forms soluble complement-activating complexes with IgG, but inhibits complement activation by IgG-coated targets. J Biol Chem. 1997;272(33):20774–81. Epub 1997/08/15. 9252400
57. Niwa H, Yamamura K, Miyazaki J, Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108(2):193–9. 1660837
58. Agarwal S, Specht CA, Haibin H, Ostroff GR, Ram S, Rice PA, et al. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. mBio. 2011;2(5).
59. Kurt-Jones EA, Mandell L, Whitney C, Padgett A, Gosselin K, Newburger PE, et al. Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood. 2002;100(5):1860–8. 12176910